# The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)

> **NCT06960629** · — · ENROLLING_BY_INVITATION · sponsor: **University Hospital Dubrava** · enrollment: 50 (estimated)

## Conditions studied

- Pseudophakic Bullous Keratopathy
- Glaucoma

## Interventions

- **DRUG:** Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06960629
- **Lead sponsor:** University Hospital Dubrava
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-04-01
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06960629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06960629, "The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06960629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*